InvestorsHub Logo
icon url

TRPL7s

11/03/13 9:06 PM

#33798 RE: DeaconY #33797

From my perspective the money they invested in an FDA expert was to avoid the cost of retooling.
In my view they had two choices one retool (expensive) or hire an FDA expert (not as expensive). I don't believe the towel has been thrown in on this current verdict. Time will tell, but in the mean time focus on potential customers who are exempt from the United States FDA requirements. Plenty of doors still to be knocked on. And as always I am completely sold on this product. Even more so after scrutinizing the competitions offering.
icon url

wshaw14

11/03/13 11:05 PM

#33799 RE: DeaconY #33797

I absolutely do not agree. "So then you agree that LEI isn't going to get the FDA variance without significant rework and costs". I would be very surprised if they did not eventually get the variance, due to their experts' experience and contacts within the departments.